PMID- 38430788
OWN - NLM
STAT- MEDLINE
DCOM- 20240422
LR  - 20240422
IS  - 1879-0046 (Electronic)
IS  - 0376-8716 (Linking)
VI  - 257
DP  - 2024 Apr 1
TI  - 3,4-Methylenedioxymethamphetamine (MDMA) impairs cognitive function during 
      withdrawal via activation of the arachidonic acid cascade in the hippocampus.
PG  - 111139
LID - S0376-8716(24)00060-7 [pii]
LID - 10.1016/j.drugalcdep.2024.111139 [doi]
AB  - BACKGROUND: The recreational drug +/-3,4-methylenedioxymethamphetamine (MDMA; also 
      known as "ecstasy") has unusual subjective prosocial and empathogenic effects, 
      and has exhibited potential as an adjunct to psychotherapy in recent years. 
      However, there has been some concern regarding possible neuropsychiatric 
      symptoms, such as cognitive impairment and dependence, emerging after abstinence. 
      Therefore, this study aimed to evaluate the mechanism underlying cognitive 
      impairment during MDMA withdrawal. To achieve this, we focused on the arachidonic 
      acid cascade, which is related to addiction to some abusive drugs. METHODS: A 
      novel object recognition task was used to investigate cognitive function in mice. 
      Furthermore, we quantified prostaglandin E(2) during MDMA withdrawal. RESULTS: 
      The recognition index significantly decreased during withdrawal after repeated 
      administration of MDMA (10mg/kg, i.p., once daily for 7 days), but not following 
      co-administration of diclofenac (10mg/kg, i.p.), a cyclooxygenase inhibitor. On 
      day 1, following repeated MDMA treatment, prostaglandin E(2) content 
      significantly increased in the hippocampus but not in the prefrontal cortex and 
      striatum. CONCLUSIONS: Our findings indicate that activation of the arachidonic 
      acid cascade at least in the hippocampus is likely involved in the development of 
      recognition memory impairment during MDMA withdrawal. Therefore, co-use of 
      cyclooxygenase inhibitors with MDMA may reduce concerns regarding MDMA-induced 
      impairment of recognition memory.
CI  - Copyright (c) 2024. Published by Elsevier B.V.
FAU - Nawata, Yoko
AU  - Nawata Y
AD  - Department of Pharmacology, Faculty of Pharmaceutical Science, Nagasaki 
      International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki 
      859-3298, Japan.
FAU - Nishioku, Tsuyoshi
AU  - Nishioku T
AD  - Department of Pharmacology, Faculty of Pharmaceutical Science, Nagasaki 
      International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki 
      859-3298, Japan.
FAU - Yamamoto, Tsuneyuki
AU  - Yamamoto T
AD  - Department of Pharmacotherapeutics and Neuropsychopharmacology, Faculty of 
      Pharmaceutical Science, Nagasaki International University, 2825-7 Huis Ten 
      Bosch, Sasebo, Nagasaki 859-3298, Japan.
FAU - Yamaguchi, Taku
AU  - Yamaguchi T
AD  - Department of Pharmacotherapeutics and Neuropsychopharmacology, Faculty of 
      Pharmaceutical Science, Nagasaki International University, 2825-7 Huis Ten 
      Bosch, Sasebo, Nagasaki 859-3298, Japan. Electronic address: ytaku@niu.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20240224
PL  - Ireland
TA  - Drug Alcohol Depend
JT  - Drug and alcohol dependence
JID - 7513587
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 0 (Prostaglandins)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/adverse effects
MH  - Arachidonic Acid/pharmacology
MH  - Cognition
MH  - Hippocampus
MH  - Prostaglandins/pharmacology
OTO - NOTNLM
OT  - Cognitive impairment
OT  - Cyclooxygenase
OT  - MDMA
OT  - Novel object recognition task
OT  - Prostaglandin E(2)
COIS- Declaration of Competing Interest On behalf of all authors, the corresponding 
      author states that there are no conflicts of interest.
EDAT- 2024/03/03 17:42
MHDA- 2024/04/22 06:42
CRDT- 2024/03/02 18:12
PHST- 2023/08/18 00:00 [received]
PHST- 2024/02/14 00:00 [revised]
PHST- 2024/02/19 00:00 [accepted]
PHST- 2024/04/22 06:42 [medline]
PHST- 2024/03/03 17:42 [pubmed]
PHST- 2024/03/02 18:12 [entrez]
AID - S0376-8716(24)00060-7 [pii]
AID - 10.1016/j.drugalcdep.2024.111139 [doi]
PST - ppublish
SO  - Drug Alcohol Depend. 2024 Apr 1;257:111139. doi: 
      10.1016/j.drugalcdep.2024.111139. Epub 2024 Feb 24.